MACROTEC
LOE ApproachingBLAINJECTIONINJECTABLE
Approved
Feb 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MACROTEC is an injectable biologic approved in 1976 by Bracco with an unknown mechanism of action and indication profile. The specific therapeutic application cannot be determined from available data, but its injection route suggests parenteral delivery for systemic effect.
LOE Approaching
As a product approaching loss of exclusivity with moderate competitive pressure (30/100), commercial teams should expect declining market share and potential headcount reduction.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MACROTEC has zero linked job openings, indicating minimal active hiring and career mobility. The LOE-approaching lifecycle stage suggests limited career advancement opportunity and potential organizational restructuring within the brand team.
Brand ManagerField Sales Representative
Worked on MACROTEC at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.